Publications by authors named "P F Curley"
Favipiravir (FVP) and remdesivir (RDV) have demonstrable antiviral activity against SARS-CoV-2. Here, the efficacy of FVP, RDV, and FVP with RDV (FVP + RDV) in combination was assessed in Syrian golden hamsters challenged with SARS-CoV- 2 (B.1.
View Article and Find Full Text PDFArticle Synopsis
- Global policymakers generally advise against using existing monoclonal antibodies like Ronapreve for COVID-19 treatment due to their reduced effectiveness against newer variants, especially Omicron.
- A study using K18-hACE2 mice showed that Ronapreve effectively reduced viral replication in the lungs and nasal areas for the Delta variant, but not for Omicron, and it prevented brain infection from Delta.
- Results indicated that Ronapreve alters the inflammatory response to the Delta variant, suggesting that while animal models can simulate treatment use cases, caution is needed in interpreting their relevance to actual treatment scenarios, particularly for Omicron.
Objective: The study evaluated physicochemical properties of eight different polymeric nanoparticles (NPs) and their interaction with lung barrier and their suitability for pulmonary drug delivery.
Methods: Eight physiochemically different NPs were fabricated from Poly lactic-co-glycolic acid (PLGA, PL) and Poly glycerol adipate-co-ω-pentadecalactone (PGA-co-PDL, PG) emulsification-solvent evaporation. Pulmonary barrier integrity was investigated using Calu-3 under air-liquid interface.
A significant challenge in the development of long-acting injectable drug formulations, especially for anti-infective agents, is delivering an efficacious dose within a tolerable injection volume. Co-administration of the extracellular matrix-degrading enzyme hyaluronidase can increase maximum tolerable injection volumes but is untested for this benefit with long-acting injectable formulations. One concern is that hyaluronidase could potentially alter the tissue response surrounding an injection depot, a response known to be important for drug release kinetics of long-acting injectable formulations.
View Article and Find Full Text PDFObjective: Health care safety net (SN) programs can potentially improve patient safety and decrease risk associated with missed or delayed follow-up care, although they require financial resources. This study aimed to assess whether the revenue generated from completion of clinically necessary recommendations for additional imaging (RAI) made possible by an IT-enabled SN program could fund the required additional labor resources.
Methods: Clinically necessary RAI generated October 21, 2019, to September 24, 2021, were tracked to resolution as of April 13, 2023.